Constipation is described as the decrease in frequency of bowel movements. It is characterized by stools that are difficult and hard to pass. Primary constipation can be caused owing to a number of lifestyle factors such as poor eating habits and decreased physical activity of an individual. On the other hand, secondary constipation can be caused owing to a variety of pathologic changes including intestinal obstruction and diseases. A number of medications can also cause constipation symptoms and this type of constipation is called as drug-induced constipation. Opioids are among such medications that could cause constipation. Opioids are classified as a class of analgesics majorly utilized medically for relieving pain by lowering the intensity of the pain signals that reach the brain.
Increasing Healthcare Costs to Fuel Opioid-induced Constipation Treatment Market
Although opioids are immensely effective for the management and treatment of pain, their regular usage may cause several side effects including constipation. Patients taking opioids suffer from acute constipation, which is referred to as opioid induced constipation (OIC). This severe type of constipation may considerably impact their lifestyle and hence a number of therapies for the treatment of opioid-induced constipation may need to be administered. The rising healthcare costs have also had a positive impact on the growth of the market. In addition, opioids are highly utilized for the treatment of chronic cancers, thus the growing incidence of cancers will boost the global opioid induced constipation treatment market.
Chloride Channel Activator Led Market in 2014
In terms of dosage form, the market for opioid induced constipation treatment is segmented into liquid, solid, and semisolid. Most medicines for opioid induced constipation are available in solid dosages such as capsules, tablets, and pills. Thus, the segment of solid dosage held the largest share in the market in 2014. This segment is predicted to maintain its superiority in the coming years.
Browse Full Global Opioid Induced Constipation Treatment Market Report with TOC :http://www.mrrse.com/opioidinduced-constipation-treatment-market
By drug class, the market is segmented into mu-opioid receptor antagonist, chloride channel activator, and others. Amongst these, the segment of chloride channel activator led the market in 2014 due to the increasing demand for Amitiza as a single drug within the market. On the other hand, mu-opioid receptor antagonist is the most swiftly developing segment due to the presence of pipeline drugs and the introduction of Moventik. The segment of mu-opioid receptor antagonist is further segmented into Relistor (Valeant), Naloxone, and Moventik (AstraZeneca). The segment of chloride channel activator is further segmented into Amitiza (Takeda). On the other hand, the others segment is further segmented into traditional laxatives and Resolor.
North America Held Largest Share in 2014
Geographically, the market is segmented into Europe, North America, Latin America, Asia Pacific, and Rest of the World (RoW). Amongst these, North America led the market in 2014 and is predicted to maintain its dominance till 2023. The reason for the superiority of this region is the rising count of individuals suffering from opioid induced constipation and the strong pipeline of drugs within this region. On the other hand, the markets in Latin America, Asia Pacific, and Rest of the World (RoW) are experiencing sluggish growth due to the absence of awareness about opioid induced constipation treatment and the comparatively lower penetration of opioids for the treatment of chronic pain.
The players dominant in the market are Abbott Laboratories, Bayer AG, C.B. Fleet Company, Inc., and Daewoong Co. Ltd., among others.